The stentless Toronto SPV bioprosthesis for aortic valve replacement

Area of Science:

• Cardiology
• Biomedical Engineering
• Surgical Innovation

Background:

• Aortic valve replacement is a critical procedure for patients with severe aortic valve disease.
• Bioprosthetic valves offer an alternative to mechanical valves, but long-term function and safety are paramount.
• The Toronto SPV bioprosthesis represents a specific innovation in prosthetic valve design.

Purpose of the Study:

• To prospectively evaluate the safety and efficacy of the Toronto SPV bioprosthesis for aortic valve replacement.
• To assess valve function using echocardiography and monitor patient outcomes.
• To determine the incidence of complications and long-term performance of the prosthesis.

Main Methods:

• Prospective evaluation of 100 patients undergoing aortic valve replacement with the Toronto SPV bioprosthesis since March 1993.
• Intraoperative transesophageal and postoperative transthoracic echocardiography for valve function assessment.
• Clinical follow-up at 6 months (74 patients) and 1 year (38 patients).

Main Results:

• Hospital mortality rate was 4%.
• One case of non-structural valve dysfunction and one case of late endocarditis requiring reoperation were reported.
• No other valve complications or clinically relevant aortic valve incompetence observed during follow-up.
• Significant decrease in transvalvular pressure gradients and left ventricular hypertrophy, with an increase in valve orifice areas.

Conclusions:

• The Toronto SPV bioprosthesis demonstrates acceptable safety and good hemodynamic performance in aortic valve replacement.
• The prosthesis is associated with significant improvements in left ventricular function and regression of hypertrophy.
• Low rates of complications suggest favorable long-term outcomes for this bioprosthetic device.